SG11201809211QA - Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans - Google Patents
Administration of butyrate, beta-hydroxybutyrate, and related compounds in humansInfo
- Publication number
- SG11201809211QA SG11201809211QA SG11201809211QA SG11201809211QA SG11201809211QA SG 11201809211Q A SG11201809211Q A SG 11201809211QA SG 11201809211Q A SG11201809211Q A SG 11201809211QA SG 11201809211Q A SG11201809211Q A SG 11201809211QA SG 11201809211Q A SG11201809211Q A SG 11201809211QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- hydroxybutyrate
- beta
- rayburn
- melissa
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 title abstract 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 title abstract 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008280 blood Substances 0.000 abstract 4
- 210000004369 blood Anatomy 0.000 abstract 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- 150000002576 ketones Chemical class 0.000 abstract 2
- 150000003626 triacylglycerols Chemical class 0.000 abstract 2
- KJDGFQJCHFJTRH-YONAWACDSA-N 16-Ketoestradiol Chemical class OC1=CC=C2[C@H]3CC[C@](C)([C@H](C(=O)C4)O)[C@@H]4[C@@H]3CCC2=C1 KJDGFQJCHFJTRH-YONAWACDSA-N 0.000 abstract 1
- 229930194542 Keto Natural products 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 abstract 1
- 229940093265 berberine Drugs 0.000 abstract 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 abstract 1
- 230000003920 cognitive function Effects 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 150000004668 long chain fatty acids Chemical class 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 229940057917 medium chain triglycerides Drugs 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 150000004666 short chain fatty acids Chemical class 0.000 abstract 1
- 235000021391 short chain fatty acids Nutrition 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662324798P | 2016-04-19 | 2016-04-19 | |
| PCT/US2017/028465 WO2017184788A1 (en) | 2016-04-19 | 2017-04-19 | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans |
| US15/491,924 US11173138B2 (en) | 2016-04-19 | 2017-04-19 | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809211QA true SG11201809211QA (en) | 2018-11-29 |
Family
ID=60039721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809211QA SG11201809211QA (en) | 2016-04-19 | 2017-04-19 | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11173138B2 (de) |
| EP (1) | EP3445355B1 (de) |
| AU (2) | AU2017253109B2 (de) |
| CA (1) | CA3021784A1 (de) |
| SG (1) | SG11201809211QA (de) |
| WO (1) | WO2017184788A1 (de) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
| US10596131B2 (en) * | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
| US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
| US10596129B2 (en) * | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
| US10245243B1 (en) * | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US10245242B1 (en) * | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
| US10596130B2 (en) * | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US11026929B2 (en) | 2016-04-19 | 2021-06-08 | Keto Patent Group, Inc. | Administration of berberine metabolites |
| WO2017208217A2 (en) | 2016-06-01 | 2017-12-07 | Aspi Ip Holder Llc | C5 ketone compositions, and related methods, for therapeutic and performance supplementation |
| US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
| GB201616058D0 (en) | 2016-09-21 | 2016-11-02 | Chain Biotechnology Ltd | Probiotic composition |
| US20180177753A1 (en) | 2016-12-23 | 2018-06-28 | Neuroenergy Ventures, Inc. | Glyceryl 3-hydroxybutyrates for migraine symptom management |
| US9925164B1 (en) | 2017-01-12 | 2018-03-27 | Neuroenergy Ventures, Inc. | Glyceryl 3-hydroxybutyrates for traumatic brain injury |
| CN110769814B (zh) | 2017-03-15 | 2022-10-18 | 睿升公司 | 具有高载药量的中链甘油三酯的药物组合物及其相关方法 |
| EP3609484A4 (de) * | 2017-04-12 | 2020-12-16 | Cavaleri, Franco | Butyrat- und beta-hydroxybutyratzusammensetzungen und verfahren zu ihrer verwendung |
| GB201710229D0 (en) * | 2017-06-27 | 2017-08-09 | Tdeltas Ltd | Compounds for new use |
| US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
| GB201715654D0 (en) | 2017-09-27 | 2017-11-08 | Tdeltas Ltd | Method of treatment |
| US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
| US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
| CN108017555B (zh) * | 2017-11-28 | 2021-03-26 | 郑州海斯威生物技术有限公司 | 一种β-羟基丁酰-氨基酸化合物及制备方法和应用 |
| US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
| WO2019161047A1 (en) * | 2018-02-14 | 2019-08-22 | Bickman Benjamin | Oral supplements of fatty acid and amino acid ketone esters to improve metabolic, physical and cognitive health |
| US11241401B2 (en) * | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
| US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
| US10512615B1 (en) | 2018-08-27 | 2019-12-24 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
| US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
| MX2021004999A (es) * | 2018-10-29 | 2021-08-11 | Keto Patent Group Inc | Administracion de butirato, beta-hidroxibutirato, cannabidiol y compuestos relacionaods en seres humanos. |
| JP2020120603A (ja) * | 2019-01-30 | 2020-08-13 | 株式会社明治 | ケトン体産生促進用組成物 |
| EP3923925A4 (de) * | 2019-02-11 | 2022-10-19 | Axcess Global Sciences, LLC | Gemischte salzsäurezusammensetzungen aus racemischem beta-hydroxybutyrat und verwendungsverfahren |
| EP3923924A4 (de) * | 2019-02-11 | 2022-11-09 | Axcess Global Sciences, LLC | Nicht-racemische beta-hydroxybutyrat-verbindungen und mit dem r-enantiomer angereicherte zusammensetzungen und verfahren zur verwendung |
| CN114072137A (zh) * | 2019-02-11 | 2022-02-18 | 阿克塞斯全球科学有限责任公司 | S-β-羟基丁酸根化合物和富含S-对映体的组合物 |
| EP3923918A4 (de) * | 2019-02-11 | 2022-10-05 | Access Global Sciences, LLC | Gemischte beta-hydroxybutyrat-salzsäurezusammensetzungen und verwendungsverfahren |
| US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| WO2021178547A1 (en) | 2020-03-05 | 2021-09-10 | Devon Price | COMPOSITION OF (D)-β-HYDROXYBUTYRIC ACID, (D)-β-HYDROXYVALERIC ACID, AND (D)-1,3 BUTANEDIOL AS A NUTRITIONAL SUPPLEMENT AND THERAPEUTIC AGENT |
| EP4125836A1 (de) * | 2020-03-27 | 2023-02-08 | Homeostasis Therapeutics, Limited | Verfahren zur behandlung von anorexia nervosa, bulimia und verwandten klinischen syndromen |
| US20230225999A1 (en) * | 2020-06-19 | 2023-07-20 | Societe Des Produits Nestle S.A. | A nutritional composition comprising 3-hydroxybutyric acid to improve the gastrointestinal barrier |
| CA3189948A1 (en) | 2020-07-23 | 2022-01-27 | Axcess Global Sciences, Llc | Administration of beta-hydroxybutyrate, and related compounds in humans for the treatment and/or prevention of respiratory illnesses |
| WO2023081409A1 (en) * | 2021-11-04 | 2023-05-11 | Keto Patent Group, Inc. | Administration of berberine metabolites |
| AU2022417093A1 (en) * | 2021-12-14 | 2024-06-13 | Suntory Holdings Limited | Beverage containing 3-hydroxybutyric acid and lower aliphatic alcohol, and method for improving taste |
| AU2022411334A1 (en) * | 2021-12-14 | 2024-06-13 | Suntory Holdings Limited | Carbonated beverage, and method for enhancing sense of carbonation of beverage |
| US20230346699A1 (en) * | 2022-04-28 | 2023-11-02 | Axcess Global Sciences, Llc | Administration of r-beta-hydroxybutyrate and related compounds in veterinary applications |
| JP7223193B1 (ja) | 2022-05-26 | 2023-02-15 | 大阪瓦斯株式会社 | 内臓脂肪低減剤およびその用途 |
| US20240065991A1 (en) * | 2022-08-26 | 2024-02-29 | Health Via Modern Nutrition Inc. | Compositions of 1,3-butanediol and beta-hydroxybutyric acid to provide optimal therapeutic ketosis |
| WO2024067626A1 (zh) * | 2022-09-27 | 2024-04-04 | 南京纽邦生物科技有限公司 | 一类酸与盐的复合物及其制备方法 |
| US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1755743A (en) * | 1928-11-02 | 1930-04-22 | Edgar H Morrison | Phonograph disk record |
| FR2745509B1 (fr) * | 1996-03-01 | 1998-04-24 | Lohr Ind | Procede de fabrication d'un corps de benne a profil concave |
| US6031000A (en) * | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
| US6380244B2 (en) * | 1998-07-22 | 2002-04-30 | Metabolix, Inc. | Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
| CN1184978C (zh) * | 2000-10-20 | 2005-01-19 | 孙喆 | 一种治疗糖尿病并发酮症酸中毒的中药 |
| GB0420856D0 (en) * | 2004-09-20 | 2004-10-20 | Ketocytonyx Inc | Cns modulators |
| EP3296284B1 (de) * | 2008-08-21 | 2021-12-01 | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health | Nicht-medizinische verwendung eines hydroxybutyratesters |
| US8642654B2 (en) * | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
| SG11201506780RA (en) * | 2013-03-19 | 2015-10-29 | Univ South Florida | Compositions and methods for producing elevated and sustained ketosis |
| US10292952B2 (en) * | 2016-03-11 | 2019-05-21 | Axcess Global Sciences, Llc | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis |
| US9925164B1 (en) * | 2017-01-12 | 2018-03-27 | Neuroenergy Ventures, Inc. | Glyceryl 3-hydroxybutyrates for traumatic brain injury |
-
2017
- 2017-04-19 WO PCT/US2017/028465 patent/WO2017184788A1/en active Application Filing
- 2017-04-19 EP EP17786592.0A patent/EP3445355B1/de active Active
- 2017-04-19 AU AU2017253109A patent/AU2017253109B2/en active Active
- 2017-04-19 SG SG11201809211QA patent/SG11201809211QA/en unknown
- 2017-04-19 US US15/491,924 patent/US11173138B2/en active Active
- 2017-04-19 CA CA3021784A patent/CA3021784A1/en active Pending
-
2023
- 2023-08-22 AU AU2023219852A patent/AU2023219852A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023219852A1 (en) | 2023-09-07 |
| EP3445355A4 (de) | 2019-12-25 |
| EP3445355B1 (de) | 2023-11-29 |
| WO2017184788A1 (en) | 2017-10-26 |
| EP3445355C0 (de) | 2023-11-29 |
| AU2017253109B2 (en) | 2023-03-23 |
| US11173138B2 (en) | 2021-11-16 |
| CA3021784A1 (en) | 2017-10-26 |
| EP3445355A1 (de) | 2019-02-27 |
| AU2017253109A1 (en) | 2018-11-15 |
| US20170296501A1 (en) | 2017-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809211QA (en) | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201809221WA (en) | Administration of berberine metabolites | |
| SG11201900975XA (en) | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201804577RA (en) | Fgf21 variants | |
| SG11201810168UA (en) | Curtain wall | |
| SG11201908320SA (en) | Method and use | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201408198QA (en) | Jumper tube locking assembly and method | |
| SG11201908789PA (en) | Method and use | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201903326RA (en) | Liposomal formulation for use in the treatment of cancer | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201908497SA (en) | Method and use | |
| SG11201900486WA (en) | Treatment and prevention of sleep disorders | |
| SG11201908751WA (en) | Method and use to prevent deposits in engine | |
| SG11201901172QA (en) | A method for manufacturing a fuel component | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201900651PA (en) | Combination of fxr agonists | |
| SG11201804587QA (en) | Isoindole compounds |